Inactive Instrument

ReNeuron Group Plc Share Price London S.E.

Equities

Biotechnology & Medical Research

Financials

Sales 2022 403K 505K 40.3M Sales 2023 530K 664K 53M Capitalization 5.17M 6.48M 517M
Net income 2022 -9M -11.27M -900M Net income 2023 -5M -6.26M -500M EV / Sales 2022 8.48 x
Net cash position 2022 13.99M 17.51M 1.4B Net cash position 2023 6.73M 8.43M 673M EV / Sales 2023 -2.94 x
P/E ratio 2022
-1.79 x
P/E ratio 2023
-0.96 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 78.26%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Operating Officer - 31/12/16
Chief Tech/Sci/R&D Officer - 02/03/22
Corporate Officer/Principal - 31/10/22
Members of the board TitleAgeSince
Director/Board Member 61 21/03/22
Chairman 71 30/06/21
Director/Board Member 61 13/07/21
More insiders
ReNeuron Group plc is a United Kingdom-based clinical-stage stem cell company. The Company is engaged in the development of stem cell therapies targeting areas of unmet or poorly met medical need. It has developed a stem cell-derived, exosome-based, drug delivery platform with customizable cellular targeting capabilities for the delivery of complex drug modalities. Through the generation of several exosome producer cell lines, its CustomEX platform can be optimized for specific tissue targets and payloads, leading to improvements in therapeutic outcome and a reduction in off-target effects. It offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalized induced pluripotent stem cell (iPSC) platform, it has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
More about the company